Autologous and Allogeneic Transplant for Relapsed Lymphoma
Status:
Completed
Trial end date:
2014-10-22
Target enrollment:
Participant gender:
Summary
The sequential combination of myeloablative therapy and autologous stem cell transplantation
(APBSCT) followed by a reduced intensity allogeneic stem cell transplant (Allo SCT) and post
SCT adoptive cellular immunotherapy will be well tolerated in patients with refractory or
recurrent non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD).